Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 2, 2011, Pages 316-326

  Tesei, Anna ^a   Leonetti, Carlo ^b   Zupi, Gabriella ^b   Scarsella, Marco ^b   Brigliadori, Giovanni ^a   Ulivi, Paola ^a   Fabbri, Francesco ^a   Arienti, Chiara ^a   Amadori, Dino ^a   Passardi, Alessandro ^a   Silvestrini, Rosella ^a   Zoli, Wainer ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Gastric cancer; Mitotic catastrophe; Sorafenib; Taxotere

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; DOCETAXEL; LISSAMINE RHODAMINE B; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2; PYRIDINE DERIVATIVE; RHODAMINE; SORAFENIB; TAXOID;

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; HUMAN; METABOLISM; MITOSIS; MOUSE; NUDE MOUSE; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZENESULFONATES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MITOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; RHODAMINES; STOMACH NEOPLASMS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 79951870237     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00993.x     Document Type: Article

References (60)

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003; 56: 1-9.
2. Pozzo C, Barone C. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist. 2008; 13: 794-806.
3. Cunningham D, Allum WH, Stenning SP, et al Perioperative chemotherapy versus surgery alone for resectable gastroe-sophageal cancer. N Engl J Med. 2006; 355: 11-20.
4. Boige V, Pignon J, Saint-Aubert B, et al Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORDO07-FFCD 9703 trial. Proc Am Soc Clin Oncol. 2007; 25: 4510a.
5. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet. 2002; 359: 1727-33.
6. Allum WH, Fogarty PJ, Stenning SP, et al Long term results of the MRC OEO2 randomized trial of surgery with or with out preoperative chemotherapy in resectable esophageal cancer. (Abstract, No. 9). 2008 Proc Gastrointest Cancers Symp. 2008: 9a.
7. Shah MA, Ramanathan RK, Ilson DH, et al Multicenter phase II study of irinote-can, cisplatin, and bevacizumab in patients with metastatic gastric or gastroe-sophageal junction adenocarcinoma. J Clin Oncol. 2006; 24: 5201-6.
8. Pinto C, Di Fabio F, Siena S, et al Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroe-sophageal junction (GEJ) adenocarcinoma (FOLCETUX study): preliminary results. Proc Am Soc Clin Oncol. 2006; 24: 4031a.
9. Moehler MH, Trarbach T, Seufferlein T, et al. AIO Gastric group. Cetuximab with irinotecan/ Na-Fa/5-FU as first line treatment in advanced gastric cancer: preliminary results of a nonrandomised multi-centre AIO phase II study. Proc Gastrointestinal Cancers Symposium. 2008: 102a.
10. Lordick F, Lorenzen S, Hegewisch-Becker S, et al Cetuximab plus weekly oxali-platin/5FU/FA /FUFOX) in 1st line metasta-tic gastric cancer. Final results from a mul-ticenter phase II study of the AIO upper GI study group. Proc Am Soc Clin Oncol. 2007; 25: 4526a.
11. Pinto C, Di Fabio F, Siena S, et al Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007; 18: 510-7.
12. Stein A, Al-Batran SE, Arnold D, et al Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. Proc Gastrointestinal Cancers Symposium. 2007: 47a.
13. Iqbal S, Goldman B, Lenz HJ, et al S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metasta-tic gastric cancer. Proc Am Soc Clin Oncol. 2007; 25: 4621a.
14. Cortés-Funes H, Rivera F, Alés I, et al Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer (AGC) with HER2/neu overexpression/ amplification. Proc Am Soc Clin Oncol. 2007; 25: 4613a.
15. Enzinger PC, Fidias P, Stuart K, et al Phase II study of bevacizumab and doc-etaxel (AVATAX) in metastatic esophageal and gastric cancer. Ann Oncol. 2006; 17: ix310 (1078PDa).
16. Ocean AJ, Schnoll-Sussman F, Chen XE, et al Recent results of phase II study of PS-341 (bortezomib) with or without irinotecan in patients with advanced gastric adenocarcinomas (AGA). Proc Am Soc Clin Oncol. 2007; 25: 45a.
17. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3: 11-22.
18. Feng W, Brown RE, Trung CD, et al Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci. 2008; 38: 195-209.
19. Wilhelm SM, Carter C, Tang L, et al BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyro-sine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 7099-109.
20. Bracarda S, Porta C, Boni C, et al Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α 2a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681 [abstract]. Proc Am Soc Clin Oncol. 2007; 25: 5100a.
21. Eisen T, Marais R, Affolter A, et al An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. Proc Am Soc Clin Oncol. 2007; 25: 8529a.
22. McDermott DF, Sosman JA, Hodi FS, et al Randomized phase II study of dacar-bazine with or without sorafenib in patients with advanced melanoma. Proc Am Soc Clin Oncol. 2007; 25: 8511a.
23. Soria J, Lazar V, Lassau N, et al Sorafenib (S) and dacarbazine (D) combination in patients (pts) with advanced malignant solid tumors: phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonogra-phy (DCE-US). Proc Am Soc Clin Oncol. 2007; 25: 3556a.
24. Richly H, Kupsch P, Passarge K, et al Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors. Proc Am Soc Clin Oncol. 2004; 22: 3049a.
25. Siu LL, Awada A, Takimoto CH, et al Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006; 12: 144-51.
26. Wallace JA, Locker G, Nattam S, et al Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a phase II trial of the University of Chicago Phase II Consortium. Proc Am Soc Clin Oncol. 2007; 25: 4608a.
27. Welch S, Hirte H, Elit L, et al CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-a trial of the PMH Phase II Consortium. Proc Am Soc Clin Oncol. 2007; 25: 5519a.
28. Awada A, Hendlisz A, Whenham N. Phase I trial to evaluate safety, pharmacokinetics, and efficacy of sorafenib combined with docetaxel in patients with advanced, refractory solid tumors. Ann Oncol. 2007; 18: 401a.
29. Flaherty KT, Brose M, Schuchter L, et al Phase I/II trial of BAY 43-9006, carbo-platin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proc Am Soc Clin Oncol. 2004; 22: 7507a.
30. Agarwala SS, Keilholz U, Hogg D, et al Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. Proc Am Soc Clin Oncol. 2007; 25: 8510a.
31. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol. 2003; 14: ii41-4.
32. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24: 4991-7.
33. Ruhstaller T, Widmer L, Schuller JC, et al Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cis-platin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol. 2009; 20: 1522-8.
34. Ajani JA, Komaki R, Putnam JB, et al A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001; 92: 279-86.
35. Bertoni L, Zoli W, Mucciolo E, et al Different genome organization in two new cell lines established from human gastric carcinoma. Cancer Genet Cytogenet. 1998; 105: 152-9.
36. Zoli W, Ricotti L, Lenzi L, et al Molecular genetics and in vitro sensitivity of a new human cell line, KKP, from a gastric adeno-carcinoma. Cancer Genet Cytogenet. 1998; 105: 43-9.
37. Skehan P, Storeng R, Scudiero D, et al New colorimetric cytotoxic assay for anticancer drug-screening. J Natl Cancer Inst. 1990; 82: 1107-12.
38. Monks A, Scudiero D, Skehan P, et al Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991; 83: 757-66.
39. Chou TC, Talalay P. Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22: 27-55.
40. Zoli W, Ricotti L, Tesei A, et al Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res. 2004; 10: 1500-7.
41. Rosetti M, Tesei A, Ulivi P, et al Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. Apoptosis. 2006; 11: 1321-30.
42. Fabbri F, Amadori D, Carloni S, et al Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J Cell Physiol. 2008; 217: 494-501.
43. Leonetti C, Biroccio A, D'Angelo C, et al Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Prostate. 2007; 67: 1475-85.
44. Geran RI, Greenberg NH, Macdonald MM, et al Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep. 1972; 3: 1-88.
45. Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2007; 1773: 1213-26.
46. Liang B, Wang S, Zhu XG, et al Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. World J Gastroenterol. 2005; 11: 623-8.
47. Yu C, Rahmani M, Almenara J, et al Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. Oncogene. 2004; 23: 1364-76.
48. Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006; 66: 1611-9.
49. Rahmani M, Davis EM, Bauer C, et al Apoptosis induced by the kinase inhibitor BAY 43 9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005; 280: 35217-27.
50. Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs. 2003; 4: 757-63.
51. Sharma A, Trivedi NR, Zimmerman MA, et al Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005; 65: 2412-21.
52. Yu C, Bruzek LM, Kaufmann SH, et al The raf kinase inhibitor BAY 43-9006 accelerates Mcl-1 degradation and regulates pro-apoptotic function. Proc Amer Assoc Cancer Res. 2005; 46: 6155a.
53. Yu C, Bruzek LM, Meng XW, et al The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005; 24: 6861-9.
54. Strumberg D, Richly H, Hilger RA, et al Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005; 23: 965-72.
55. Domina AM, Smith JH, Craig RW. Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition. J Biol Chem. 2000; 275: 21688-94.
56. Domina AM, Vrana JA, Gregory MA, et al MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004; 23: 5301-15.
57. Milella M, Kornblau SM, Estrov Z, et al Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001; 108: 851-9.
58. Meng XW, Chandra J, Loegering D, et al Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J Biol Chem. 2003; 278: 47326-39.
59. Yu HG, Ai YW, Yu LL, et al Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresis-tance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer. 2008; 122: 433-43.
60. Maeta Y, Tsujitani S, Matsumoto S, et al Expression of Mcl-1 and p53 proteins predicts the survival of patients with T3 gastric carcinoma. Gastric Cancer. 2004; 7: 78-84.